Compare WRLD & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | WVE |
|---|---|---|
| Founded | 1962 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.3M | 957.7M |
| IPO Year | 1994 | 2015 |
| Metric | WRLD | WVE |
|---|---|---|
| Price | $184.90 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $29.81 |
| AVG Volume (30 Days) | 45.2K | ★ 3.1M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $585,166,700.00 | $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | $85.67 |
| P/E Ratio | $143.42 | ★ N/A |
| Revenue Growth | 3.60 | ★ 149.43 |
| 52 Week Low | $110.00 | $4.56 |
| 52 Week High | $227.68 | $21.73 |
| Indicator | WRLD | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 34.14 |
| Support Level | $191.81 | N/A |
| Resistance Level | $197.42 | $6.33 |
| Average True Range (ATR) | 5.21 | 0.21 |
| MACD | 0.38 | -0.02 |
| Stochastic Oscillator | 71.55 | 10.53 |
World Acceptance Corp operates a small-loan consumer finance (installment loan) business. It offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. The Company generally serves individuals with limited access to other sources of consumer credit such as banks, credit unions, other consumer finance businesses and credit card lenders. The Company also offers income tax return preparation services to its loan customers and other individuals. The traditional installment loan industry is a fragmented segment of the consumer lending industry. The Company has one reportable segment: the consumer finance segment.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.